Format

Send to

Choose Destination
  • PMID: 28376218 was deleted because it is a duplicate of PMID: 27794123
J Natl Cancer Inst. 2016 Oct 28;109(2). pii: djw206. Print 2017 Feb.

BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.

Author information

1
Mailman School of Public Health, Columbia University, New York, NY, USA.
2
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
3
College of Physicians and Surgeons, Columbia University, New York, NY, USA.
4
Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.

Abstract

Background:

Lifestyle factors may be associated with chemotherapy-induced peripheral neuropathy (CIPN). We examined associations between body mass index (BMI) and lifestyle factors with CIPN in the Pathways Study, a prospective cohort of women with invasive breast cancer.

Methods:

Analyses included 1237 women who received taxane treatment and provided data on neurotoxicity symptoms. Baseline interviews assessed BMI (normal: <25 kg/m2; overweight: 25-29.9 kg/m2; obese: ≥30 kg/m2), moderate-to-vigorous physical activity (MVPA) (low: <2.5; medium: 2.5-5; high: >5 hours/week) and fruit/vegetable intake (low: <35 servings/week; high: ≥35 servings/week). Baseline and six-month interviews assessed antioxidant supplement use (nonuser, discontinued, continued user, initiator). CIPN was assessed at baseline, six months, and 24 months using the Functional Assessment of Cancer Therapy-Taxane Neurotoxicity (FACT-NTX); a 10% decrease was considered clinically meaningful.

Results:

At baseline, 65.6% of patients in the sample were overweight or obese, 29.9% had low MVPA, 57.5% had low fruit/vegetable intake, and 9.5% reported antioxidant supplement use during treatment. In multivariable analyses, increased CIPN was more likely to occur in overweight (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.19 to 4.88) and obese patients (OR = 3.21, 95% CI = 1.52 to 7.02) compared with normal weight patients at 24 months and less likely to occur in patients with high MVPA compared with those with low MVPA at six (OR = 0.56, 95% CI = 0.34 to 0.94) and 24 months (OR = 0.43, 95% CI = 0.21 to 0.87). Compared with nonusers, patients who initiated antioxidant use during treatment were more likely to report increased CIPN at six months (OR = 3.81, 95% CI = 1.82 to 8.04).

Conclusions:

Obesity and low MVPA were associated with CIPN in breast cancer patients who received taxane treatment.

Comment in

PMID:
27794123
PMCID:
PMC6093415
DOI:
10.1093/jnci/djw206
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center